iTeos Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on the Nasdaq Global Market (NASDAQ: ITOS), with its principal executive office in Watertown, Massachusetts, United States, and a research center in Gosselies, Belgium. For French-speaking investors in France, Belgium, and Switzerland, iTeos is best understood as a clinical-stage oncology company with a research-heavy, high-risk profile rather than a commercial-stage pharma group. The company was incorporated in Delaware in October 2019 as the successor to iTeos Belgium SA, which was founded in Belgium in 2011. That transatlantic footprint matters: it reflects a development model built around scientific discovery, translational biology, and early-stage clinical execution across both the United States and Europe. iTeos has focused on immuno-oncology, especially tumor resistance pathways that can limit the effectiveness of checkpoint inhibitors. Its lead asset has been belrestotug, an anti-TIGIT monoclonal antibody designed to be used alone or, more importantly, in combination with agents such as dostarlimab. In its annual reporting, the company has also discussed other pipeline assets, including EOS-984, a small-molecule oncology program, alongside additional exploratory research efforts aimed at addressing immune suppression in solid tumors. Competitively, iTeos operates in one of the most crowded areas of modern oncology, where large pharmaceutical companies and specialist biotech firms are all pursuing similar immuno-oncology targets. Its differentiation has historically rested on target selection, mechanistic depth, and the use of combination regimens intended to unlock patient responses beyond what monotherapy can achieve. However, its recent history shows the volatility of clinical biotech investing. In May 2025, iTeos reported unfavorable interim results from its GALAXIES Lung-201 program, and GSK later confirmed the end of the belrestotug development program. Following that setback, iTeos initiated a strategic review, and in July 2025 it announced an agreement to be acquired by Concentra Biosciences. That sequence is highly significant for investors: it highlights how quickly valuation can change when a company depends on a small number of clinical assets and one lead program fails to meet efficacy expectations. As a result, iTeos remains relevant as a Nasdaq-listed U.S. biotech with an international research base, but it is now best viewed through the lens of strategic repositioning and capital structure change rather than simple pipeline expansion.